LifeStance Health Group Inc · Q3 2023 earnings

Briefing

LifeStance's Q3 2023 results reflected a strong revenue growth driven by net clinician growth and increased visit volumes, but were impacted by a net loss due to stock-based compensation and a settlement.

LifeStance Health Group reported a 21% increase in total revenue, reaching $262.9 million. The company experienced a net loss of $61.6 million, influenced by stock-based compensation expenses and a preliminarily approved settlement. The company is raising the midpoints of full year Revenue, Center Margin, and Adjusted EBITDA guidance ranges.

• Total revenue increased by 21% to $262.9 million.
• Total clinicians reached 6,418, up 18% year-over-year.
• Net loss amounted to $61.6 million, impacted by stock-based compensation and a settlement.
• Adjusted EBITDA decreased by 5% to $14.6 million.

Headline financials

Revenue & EPS history

LifeStance is raising the midpoints of full year Revenue, Center Margin, and Adjusted EBITDA guidance ranges, with the following outlook for 2023: The Company expects full year revenue of $1.03 to $1.04 billion, Center Margin of $292 to $300 million, and Adjusted EBITDA of $56 to $60 million. For the fourth quarter of 2023, the Company expects total revenue of $255 to $265 million, Center Margin of $73 to $81 million, and Adjusted EBITDA of $17 to $21 million.